Single-photon emission computed tomographic imaging of the early time course of therapy-induced cell death using technetium 99m tricarbonyl his-annexin A5 in a colorectal cancer xenograft model

Molecular Imaging

Volumn 11, Issue 2, 2012, Pages 135-147

  Vangestel, Christel ^a,b,c,d   Van De Wiele, Christophe ^a,b,c,d   Mees, Gilles ^a,b,c,d   Mertens, Koen ^a,b,c,d   Staelens, Steven ^a,b,c,d   Reutelingsperger, Chris ^a,b,c,d   Pauwels, Patrick ^a,b,c,d   Van Damme, Nancy ^a,b,c,d   Peeters, Marc ^a,b,c,d  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c GHENT UNIVERSITY   (Belgium)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

5-FLUOROURACIL; ANNEXINS; ANTI-APOPTOSIS; AUTOPHAGY; BEVACIZUMAB; CASPASE-3; COLORECTAL CANCER; CORRELATION COEFFICIENT; EMISSION COMPUTED TOMOGRAPHY; IMMUNOSTAINING; IRINOTECAN; OPTIMAL TIMING; OXALIPLATIN; POST TREATMENT; SINGLE PHOTON EMISSION; SINGLE-DOSE; SURVIVIN; TECHNETIUM-99M; TIME COURSE; TOMOGRAPHIC IMAGING; TREATMENT GROUP;

ANTIBIOTICS; COMPUTERIZED TOMOGRAPHY; DISEASES; MAMMALS; PARTICLE BEAMS; RADIOACTIVE TRACERS; TECHNETIUM; TUMORS;

CELL DEATH;

ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, MOUSE; CASPASE 3; DIAGNOSTIC AGENT; INHIBITOR OF APOPTOSIS PROTEIN; LIPOCORTIN 5; MAP1LC3 PROTEIN, MOUSE; MICROTUBULE ASSOCIATED PROTEIN; REPRESSOR PROTEIN; TECHNETIUM; TECHNETIUM 99M TRICARBONYL HIS ANNEXIN A5; TECHNETIUM 99M TRICARBONYL HIS-ANNEXIN A5; TECHNETIUM COMPLEX;

ANIMAL; ARTICLE; CELL DEATH; COLORECTAL TUMOR; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; MOUSE; PATHOLOGY; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TIME; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANNEXIN A5; ANTINEOPLASTIC AGENTS; CASPASE 3; CELL DEATH; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MICROTUBULE-ASSOCIATED PROTEINS; ORGANOTECHNETIUM COMPOUNDS; REPRESSOR PROTEINS; TECHNETIUM; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84860713531     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2011.00034     Document Type: Article

References (35)

1. Gerl R, Vaux DL. Apoptosis in the development and treatment of cancer. Carcinogenesis 2005;26:263-70, doi:10.1093/carcin/bgh283. (Pubitemid 40246548)
2. de Bruin EC, Medema JP. Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treat Rev 2008;34:737-49, doi:10.1016/j.ctrv.2008.07.001.
3. Zwaal RFA, Comfurius P, Bevers EM. Surface exposure of phosphatidylserine in pathological cells. Cell Mol Life Sci 2005; 62:971-88, doi:10.1007/s00018- 005-4527-3. (Pubitemid 40655614)
4. Blankenberg FG. In vivo detection of apoptosis. J Nucl Med 2008; 49 Suppl:81-95, doi:10.2967/jnumed.107.045898. (Pubitemid 351948038)
5. Brouckaert G, Kalai M, Krysko DV, et al. Phagocytosis of necrotic cells by macrophages is phosphatidylserine dependent and does not induce inflammatory cytokine production. Mol Biol Cell 2004; 5:1089-100. (Pubitemid 38316218)
6. Eom YW, Kim MA, Park SS, et al. Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. Oncogene 2005;24:4765-77, doi:10.1038/sj.onc. 1208627. (Pubitemid 41076294)
7. 99mTc- HYNIC-rh-annexin A5 scintigraphy: visual and quantitative evaluation of early treatment-induced apoptosis to predict treatment outcome. Nucl Med Commun 2008;29:39-44, doi:10.1097/ MNM.0b013e3282f1bc22. (Pubitemid 351339339)
8. 99mTchydrazinonicotinamide- annexin A5 imaging for predicting response to chemotherapy. J Nucl Med 2006;47:1813-8. (Pubitemid 47545004)
9. 99mTc]-labeled tricarbonyl His-annexin A5 as an imaging agent for the detection of phosphatidylserine-expressing cells. Nucl Med Biol 2010;37:965-75, doi:10.1016/j.nucmedbio.2010.06.007.
10. 99mTcannexin V. J Nucl Med 2003;44:92-7. (Pubitemid 36077718)
11. Leist M, Jaättelä M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2001;2:589-98, doi:10.1038/35085008. (Pubitemid 33674010)
12. Epstein RJ. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic. Cancer Metastasis Rev 2007;26:443-52, doi:10.1007/s10555-007- 9071-1. (Pubitemid 350115101)
13. Myers AL, Williams RF, Ng CY, et al. Bevacizumab-induced tumor vessel remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation. J Pediatr Surg 2010;45: 1080-5, doi:10.1016/j.jpedsurg.2010.02.068.
14. McGee MC, Hamner JB, Williams RF, et al. Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys 2010;76:1537-45, doi:10.1016/j.ijrobp.2009.12.010.
15. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34, doi:10.1200/JCO.2007.14.7116.
16. Wild R, Fager K, Flefleh C, et al. Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. Mol Cancer Ther 2006;5:104-13, doi:10.1158/ 1535-7163.MCT-05-0259.
17. Brink M, de Goeij AFPM, Weijenberg MP, et al. K-ras oncogene mutation in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 2003;24:703-10, doi:10.1093/carcin/bgg009. (Pubitemid 36592405)
18. Capdevila J, Elez E, Macarulla T, et al. Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treat Rev 2009;35:354-63, doi:10.1016/j.ctrv.2009.02.001.
19. Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev 2005;5: 726-34, doi:10.1038/nrc1692. (Pubitemid 41486365)
20. Mizushima N. Methods for monitoring autophagy. Int J Biochem Cell Biol 2004;36:2491-502, doi:10.1016/j.biocel.2004.02.005. (Pubitemid 39119761)
21. Yoshioka A, Miyata H, Doki Y, et al. LC3, an autophagosome marker, is highly expressed in gastrointestinal cancers. Int J Oncol 2008;33:461-8.
22. Giannopoulou E, Antonacopulou A, Matsouka P, Kalofonos HP. Autophagy: novel action of panitumumab in colon cancer. Anticancer Res 2009;29:5077-82.
23. Altieri DC. Survivin in apoptosis control and cell cycle regulation in cancer. Prog Cell Cycle Res 2003;5:447-52.
24. Kawasaki H, Altieri DC, Lu C-D, et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998;58:5071-4. (Pubitemid 28521163)
25. Angell H. A study into the potential role of survivin localization in resistance to drug-induced apoptosis. Biosci Horiz 2008;1:85-91, doi:10.1093/biohorizons/hzn012.
26. Zhang H-Y, Meng X, Du Z-X, et al. Significance of survivin, caspase-3, and VEGF expression in thyroid carcinoma. Clin Exp Med 2009;9:207-13, doi:10.1007/s10238-009-0031-7.
27. 99mTc annexin V. J NuclMed 1999;40:184-91. (Pubitemid 29044190)
28. 99mHYNIC- annexin V: a potential for the in-vivo detection of apoptosis. J Eur J Nucl Med 1999;26:1251-8, doi:10.1007/s002590050580. (Pubitemid 29467018)
29. Tait F, Cerqueira MD, Dewurst TA, et al. Evaluation of annexin V as a platelet-directed thrombus targeting agent. Thromb Res 1994; 75:491-501, doi:10.1016/0049-3848(94)90224-0. (Pubitemid 24267333)
30. Blankenberg F. To scan or not to scan, it is a question of timing: technetium-99m-annexin V radionuclide imaging assessment of treatment efficacy after one course of chemotherapy. Clin Cancer Res 2002;8:2757-68.
31. 99mTc-annexin V uptake and histologic findings in an experimental model. J Nucl Med 2004;45:2083-7. (Pubitemid 47611639)
32. Mandl SJ, Mari C, Edinger M, et al. Multi-modality imaging identifies key times for annexin V imaging as an early predictor of therapeutic outcome. Mol Imaging 2004;3:1-8, doi:10.1162/ 153535004773861679.
33. Van de Wiele C, Lahorte C, Vermeersch H, et al. Quantitative tumor apoptosis imaging using technetium-99m-HYNIC annexin V single positron emission computed tomography. J Clin Oncol 2003;21:3483-7, doi:10.1200/JCO.2003.12.096. (Pubitemid 46594081)
34. 99mTc-HYNIC-rh-annexin A5 scintigraphy during platinum-based chemotherapy in advanced lung cancer. J Clin Oncol 2007;25:2534-9, doi:10.1200/JCO.2006.10.1337. (Pubitemid 47041226)
35. 99mTc-annexin A5 scintigraphy: visual analysis in relation to treatment response. Radiol Oncol 2004;72: 333-9, doi:10.1016/j.radonc.2004.07.008. (Pubitemid 39265388)